Bio­gen makes cau­tious bet on dry AMD as part­ner Cat­a­lyst Bio moves an­ti-C3 drug to­ward the clin­ic

Mov­ing deep­er in­to oph­thal­mol­o­gy, Bio­gen has picked up a pre­clin­i­cal can­di­date for dry age-re­lat­ed mac­u­lar de­gen­er­a­tion.

Their part­ner of choice is Cat­a­lyst Bio, a biotech bet­ter known for its he­mo­phil­ia ef­forts (not to be con­fused with rare neu­ro­log­i­cal dis­ease-fo­cused Cat­a­lyst Phar­ma). For $15 mil­lion up­front and $340 mil­lion in mile­stones, Bio­gen will take over from the IND-en­abling stage on­ward once Cat­a­lyst Bio com­pletes the ear­ly re­search and man­u­fac­tur­ing work — which Bio­gen will fund.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.